NASDAQ$CMPS
COMPASS Pathways plc · Q4 2021 earnings
Q4 2021 earnings · · Investor relations
Briefing
Reported financial results for Q4 and full year 2021 and provided a business update.
COMPASS Pathways reported a net loss for the quarter ended December 31, 2021, was $25.7 million, or $0.61 loss per share. The company's cash and cash equivalents were $273.2 million as of December 31, 2021.
- Positive results from phase IIb COMP360 psilocybin therapy trial for treatment-resistant depression (TRD); rapid and sustained response for patients receiving a single 25mg dose of COMP360 psilocybin with psychological support
- Positive results from open-label study of 25mg COMP360 psilocybin therapy as adjunct to SSRI antidepressants in TRD
- Launch of phase II study of COMP360 psilocybin therapy for post-traumatic stress disorder (PTSD)
- New senior executives appointed: Dr Guy Goodwin as Chief Medical Officer, Mike Falvey as Chief Financial Officer and Matt Owens as General Counsel and Chief Legal Officer
Headline financials
Revenue & EPS history
COMPASS · Revenue · Quarterly
$0
Forward guidance
The company is preparing for phase III trials.
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 18 quarterly earnings reports · overlaid with Q4 2021
-0.7%
Avg return
Earnings day
+0.6%
Avg return
5 days after
+4.1%
Avg return
30 days after
32%
6 / 19 earnings
Positive
+25.1%
Q2 2022
Best reaction
-23.3%
Q3 2024
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q4 2026 | -5.9% | +12.7% | +29.1% | |
| Q3 2025 | -0.5% | +4.7% | -12.3% | |
| Q1 2025 | +0.5% | +4.3% | +28.3% | |
| Q4 2024 | +5.9% | +4.1% | -20.5% | |
| Q3 2024 | -23.3% | -27.0% | -25.8% | |
| Q1 2024 | +0.0% | -4.9% | -18.7% | |
| Q4 2023 | -7.2% | -12.1% | -32.7% | |
| Q3 2023 | +10.9% | +4.7% | +5.5% | |
| Q2 2023 | -4.7% | -8.8% | +4.2% | |
| Q1 2023 | -4.1% | -2.3% | -8.7% | |
| Q4 2022 | -3.4% | +0.8% | +23.3% | |
| Q3 2022 | +2.0% | -3.9% | +14.4% | |
| Q2 2022 | +25.1% | +18.1% | +4.6% | |
| Q1 2022 | -8.2% | +3.7% | +33.0% | |
| Q4 2021 | +8.1% | +15.5% | -1.1% | |
| Q2 2021 | -5.8% | -8.1% | +5.4% | |
| Q4 2020 | -1.2% | +4.5% | -5.9% | |
| Q4 2019 | -1.2% | +4.5% | -5.9% | |
| Q3 2020 | -0.2% | +1.4% | +61.6% | |
| Q1 2020 | — | — | — | |
| Q3 2019 | — | — | — | |
| Q2 2019 | — | — | — | |
| Q1 2019 | — | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro